Shanghai and Singapore, July 22^nd, 2024, ClinChoice, a global full-service clinical CRO (Contract Research Organization), and YAFO Capital, a leading boutique investment and advisory firm announced today a strategic partnership that will combine their market-leading capabilities in service of Chinese biotech and pharma customers. Together, the companies will bring to market a state-of-the-art international asset transfer and incubator platform that will accelerate the launch of China’s innovative drugs in oversea markets. The incubator will assist biotech and pharma companies to identify development partner and investor, and move their assets to oversea for further development and commercialization, to create greater value for the asset holding biotech and pharma.

上海和新加坡，2024年7月22日：今日，雅法资本与ClinChoice昆翎达成战略合作，双方将运用各自优势，深化多维度合作，重点包括共同打造国际孵化器平台，加持中国创新药的出海战略，助力国内外药企的跨境业务与交易，为客户的可持续发展创造更大的价值。

In recent years, the oversea market has gradually become the focus of Chinese innovative drug companies as a strategic layout for long-term development. Since 2023, China's innovative drugs "going overseas" have ushered in scalable growth. In 2023, China's innovative drugs accomplished nearly 70 license-out transactions with a total disclosed transaction amount of over $35 billion. Up to now, the number of license-out deals continues to grow and set new records. It can be seen that Chinese pharmaceutical companies are increasingly recognized by the international counterparties, and innovative drugs "going overseas" continue to maintain the growth trend. In addition to Europe and the United States, where heavyweight deals are frequently publicly released, Southeast Asia is becoming a popular place due to its large population, improving economy, maturing regulatory processes and healthcare systems.

近年来，海外市场作为中国创新药企长远发展的战略布局已逐渐成为焦点。自2023年起，中国创新药的“出海”迎来了规模空前的增长。2023年，国内共发生近70笔创新药License-out（对外授权）交易，已披露交易总金额超350亿美元。截止目前，License-out的交易数量持续增长，也不断刷新记录。由此可见，中国药企越来越受到国际认可，“出海”也依旧保持着增长态势，除了重磅交易频传的欧美市场，在东南亚市场，随着人口红利、经济提升、医疗系统和监管流程的日趋成熟，也日渐成为药企“出海”的热门地。

YAFO Capital is a boutique investment and advisory firm specializing in biopharmaceutical investment and financing, cross-border asset transactions and asset incubation in China and overseas markets. The Company has been equipped with professional teams in the United States, Japan, Europe and other major pharmaceutical innovation regions around the world. In the past decade, YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies.

雅法资本是一家致力于中国及海外生物医药投融资、资产跨境交易和资产孵化的新型投资和投行咨询机构。全球交易团队覆盖美国、日本 、欧洲等全球主要医药创新区域。在过去十年成功推进了大量的海外项目进入中国市场并协助诸多中国产品完成海外授权。

ClinChoice is a global clinical CRO and dedicated to providing full-service and functional solutions across the entire development lifecycle for pharmaceutical, biotechnology, medical device, and consumer product companies locally and globally. With the focus of customer-centric industry development, the Company has acquired CROMSOURCE, a European clinical CRO headquartered in Italy, and CSI, a Southeast Asia clinical CRO headquartered in Singapore, to continue to expand overseas, deepen and improve its professional strengths and teams, and consolidate its ability and potential to offer professional services for customers worldwide.

ClinChoice昆翎，作为一家全球布局的临床CRO，始终致力于为本土和全球的制药、生物医药、医疗器械和消费者健康公司提供贯穿整个研发生命周期的全服务和专业解决方案。公司着眼行业发展，立足客户需求，先后收购总部位于意大利欧洲临床CRO CROMSOURCE以及总部位于新加坡的东南亚临床CRO CSI，持续拓展国际版图，不断深化和完善专业优势和团队，夯实为全球客户提供专业服务的能力和潜力。

Mr. Sean Jiang, Founder and CEO of YAFO Capital, said, "We are very much looking forward to cooperating with ClinChoice. We are committed to helping Chinese healthcare companies to go global with their high-quality assets. ClinChoice’s strong clinical services and strategic support, as well as its capability to implement such services in Southeast Asia, combined with YAFO Capital's rich global network and transaction experience, will create opportunities for more Chinese innovative drugs in different categories to go overseas and benefit more patients."

雅法资本创始人及CEO蒋晓阳先生表示：“我们非常期待与昆翎的合作，雅法资本致力于为中国医疗企业的优质资产链接全球市场，昆翎强大的临床服务与策略支持以及东南亚的落地能力，联合雅法丰富的全球网络以及交易经验，将为更多不同类别的中国创新药提供出海的机会，惠及更多的病人。“

"We are very excited to partner with YAFO Capital on this ground-breaking initiative.” said Mr. Ling Zhen, Global Chairman and CEO of ClinChoice, “At ClinChoice, we are committed to working closely with our partners to build a global full-service clinical R&D ecosystem. By joining forces, we are leveraging our professional strengths and global network, especially our resources in the Southeast Asia market, together with YAFO Capital's rich pharmaceutical cross-border transaction experience and global transaction teams, to tap into a high-quality potential product pipeline, with a final purpose of bringing more possibilities for China's innovative drugs going global."

ClinChoice 昆翎全球董事长兼CEO甄岭先生表示：“我们非常荣幸能与雅法资本展开合作。一直以来，昆翎携手行业伙伴力求打造一个全球化的全服务临床研发生态系统。此次强强联手，我们运用自身的专业优势、全球化的网络，尤其在东南亚市场的资源，叠加雅法资本丰富的医药跨境交易经验和全球交易团队，挖掘优质潜在的产品管线，为中国的创新药带来更多可能，逐梦全球。”

About ClinChoice  关于ClinChoice昆翎

ClinChoice is a global clinical CRO dedicated to offering high-quality services to pharmaceutical, biotechnology, medical device, and consumer product companies.  These services include Clinical Operations, Project Management, Biostatistics, Data Management, Regulatory Affairs, Medical Affairs, Pharmacovigilance, and other product development services. ClinChoice employs more than 4,000 dedicated professionals in 30 different countries across Asia, Europe and North America around the world. For more information, visit www.clinchoice.com.cn

ClinChoice昆翎是一家全球领先的合同研究组织（Contract Research Organization，CRO），致力于为本土和全球的制药、生物医药、医疗器械和消费者健康公司提供贯穿整个研发生命周期的全服务和专业解决方案。专业服务领域包括：临床运营、项目管理、生物统计、数据管理、统计编程、注册事务、医学事务、可行性研究、人类遗传资源管理、临床安全管理、天然药/中医药及临床I期服务等。目前，ClinChoice 昆翎在亚洲、欧洲和北美的 30 多个国家和地区拥有 4,000 多名专业人员为客户提供全方位服务。更多详情，敬请访问：www.clinchoice.com.cn 

About YAFO Capital关于雅法资本

Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com

雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。雅法全球医疗专注于医药跨境、国内授权和并购交易，基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。更多详情，敬请访问 ：www.yafocapital.com

Recent YAFO Events近期雅法活动

2024-09 ACCESS CHINA Autumn Roadshow, Virtual & Yunnan 药通中国秋季路演，线上&云南

2025-01 ACCESS CHINA @ JPM Week, Virtual & San Francisco药通中国论坛@JPM，线上&旧金山

Read more here 详情请点击阅读原文

https://biotochina.org/

Contact YAFO联系雅法 

Wendi Xiang, Vice President | 相文迪  副总裁

YAFO Capital (Shanghai) 雅法资本

Mobile: +86-13733685995

Email: wxiang@yafocapital.com

Web: www.yafocapital.com